JAM3 biomarker study for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at a protein called JAM3 in bladder cancer that has grown into the muscle layer. It aims to see if JAM3 levels can predict how well chemotherapy works and how long patients might live.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with transitional cell carcinoma (a common type of bladder cancer).
- Your cancer has invaded the muscle layer of the bladder (muscle-invasive bladder cancer).
- You are eligible to receive chemotherapy before surgery (neoadjuvant chemotherapy).
- Your cancer has not spread to other parts of the body (no metastatic disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor and blood samples from people with muscle-invasive bladder cancer to find markers that help predict how the disease will progress. It aims to improve personalized treatment for those with this specific stage of bladder cancer.
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
This study looks at tissue from bladder cancer surgeries to understand how immune cells and surrounding tissue interact. It may help find better ways to treat bladder cancer in the future, but it does not involve new treatments for participants.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
This trial tests a combination of two medications, disitamab vedotin and toripalimab, to treat bladder cancer that has grown into the muscle layer of the bladder. The goal is to see if this treatment can save the bladder while effectively fighting the cancer.
Hear when a new Urothelial Carcinoma Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.